BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis; herpes simplex virus (HSV) Inhibiting CXCL1 or its receptor, CXCR2, could treat encephalitis caused by HSV-1. In mice with HSV-1 encephalitis, systemic knockout of CXCR2 lowered disease scores, improved survival and reduced...
BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...balixafortide in China, initially for metastatic breast cancer. Polyphor will retain all rights to the CXCR4...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Jul 31, 2020
Finance

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

...it expects the first readout of overall response rate data for lead program balixafortide. The CXCR4...
...usually is chemotherapy following treatment with a CDK4/6 inhibitor; and into a basket trial of CXCR4-high...
...CDK4 - Cyclin dependent kinase 4 CDK6 - Cyclin dependent kinase 6 CXCR4 (NPY3R) - CXC chemokine receptor 4...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

...Janus kinase-2 Hongjiang Li, Staff Writer Bruton's tyrosine kinase (Btk) CD83 Janus kinase-2 (JAK-2) Janus kinase-1 (JAK-1) Calcineurin CD40 CD80 (B7-1) CD86 (B7-2) CXC chemokine receptor 4 (CXCR4) (NPY3R...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

...trafficking into the tumor, and lack of persistence. MILs have increased expression of chemokine receptor CXCR4...
...covering MILs, compositions containing them and methods of manufacturing and use Targets CXCR4 (NPY3R) - CXC chemokine receptor 4 Elizabeth...
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...GmbH and Scintomics GmbH is developing the products as a theranostic radiopharmaceutical pair targeting the CXCR4...
...through Phase IIb testing (see "Inotrem Raises €39M Series B" ). Targets CXCR4 (NPY3R) - CXC chemokine receptor 4...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Dec 19, 2019

CXCR2 inhibition could overcome androgen receptor antagonist resistance in prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Inhibiting CXCR2 could treat androgen receptor antagonist-resistant prostate cancer. Knockout of CXCR2, which is found on treatment-resistant, androgen receptor-negative neuroendocrine tumor cells in heterogeneous prostate cancers, restored sensitivity to...
Items per page:
1 - 10 of 624